LCC Advances in ALK+ Cancer in Cantonese
As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with Dr. Tony Mok, Dr. Chao Zhang, and Dr. Wen-Zhao Zhong. The...
14 Aug 46min
FDA Approval: Zidesamtinib and ROS1 NSCLC
Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephe...
28 Jul 24min
Rewriting the Playbook: Cellular Therapy and Vaccines for ALK-Positive Lung Cancer
How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore ...
21 Jul 47min
IASLC - Your First Faculty Job
Starting your first faculty position can be both exciting and overwhelming. In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Arthi Sridhar to discuss the transition ...
7 Jul 41min
Game Changers & Hard Truths: Dr. Balazs Halmos Unfiltered
In this episode of Lung Cancer Considered, Dr. Balazs Halmos reflects on a career at the forefront of thoracic oncology, sharing the pivotal moments, lessons learned, and hard truths that have shaped ...
23 Jun 45min
Welcome to Seoul: 2026 World Conference on Lung Cancer (WCLC) Preview
This episode of Lung Cancer Considered provide a preview of the upcoming IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea this September. Key topics covered include WCLC26 highlights -...
12 Jun 39min
ASCO 2026 Highlights – Part 2: Emerging Immunotherapy Strategies in Lung Cancer
In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy adva...
9 Jun 40min
